Sabinsa secures USP GMP Audited status for three sites

May 22, 2019
Sebastian Krawiec

The Kunigal, and Dobaspet units in Bengaluru, India, and the Hyderabad unit in Telangana state, India have been audited by the United States Pharmacopeia (USP) and received GMP compliance certificates.

Three Sami-Sabinsa Group Manufacturing units - the Kunigal, and Dobaspet units in Bengaluru, India, and the Hyderabad unit in Telangana state, India - have been audited by the United States Pharmacopeia (USP) and received GMP compliance certificates. The company’s Nelamangala site in Bengaluru already received a USP GMP certificate earlier this year. The USP GMP certificate recognizes that the facilities operate GMP quality systems which meet the requirements set forth by 21 CFR Part 117 Current Good Manufacturing Practice, Hazard Analysis and Risk-Based Preventive Controls for Human Food, and USP-NF general chapter <2750> Manufacturing Practices for Dietary Supplements for Dietary Ingredient Manufacturing.

“USP is pleased to recognize Sabinsa’s successful completion of the USP Quality Systems GMP Audit Program for this facility,” said John Atwater, senior director of USP Verification Services, in a press release. “This demonstrates Sabinsa’s commitment to quality and to operating GMP quality systems for the manufacture of dietary ingredients in compliance with officially recognized requirements.”

The Kunigal and Hyberabad units are equipped to handle batch extractions, while the Dobaspet unit is equipped with continuous extractors made entirely of stainless steel 316 which can extract more than 40 tons of herbal raw material per day. Both these units are also NSF-GMP certified. 

Related Content:

Trends & Business